2310015B20Rik Inhibitors
2310015B20Rik Inhibitors represents a specialized group of compounds designed to interact with the protein expressed by the gene 2310015B20Rik. The development of these inhibitors is a multi-faceted process, deeply rooted in molecular biology and chemistry. Initial steps in identifying potential inhibitors involve a comprehensive understanding of the protein's structure and biological role. This foundational knowledge is crucial in guiding the design or selection of molecules that can specifically target and modulate the protein's activity. Advanced computational techniques, including molecular docking and simulations, are employed to predict how various chemicals may interact with the protein. These in silico models provide a preliminary filter, identifying compounds with the highest potential for interaction based on their structural compatibility and binding affinity.
Subsequently, these computationally identified candidates undergo experimental validation. High-throughput screening (HTS) is a standard approach in this phase, where a large array of chemicals is tested for their ability to influence the activity of 2310015B20Rik. This technique is instrumental in narrowing down the vast pool of inhibitors to a more manageable number of promising candidates. Following HTS, in vitro assays are conducted to confirm the direct interaction between the inhibitors and the protein, and to evaluate their specificity and potency. These assays are critical in ensuring that the identified inhibitors effectively target the intended protein without significant off-target effects. The range of mechanisms employed by these inhibitors can vary substantially. Some might directly bind to the protein's active site, thereby obstructing its functional domain. Others could interact with allosteric sites, altering the protein's structure and consequently its activity.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits the mammalian target of rapamycin (mTOR), a crucial protein kinase for cell growth and proliferation. It acts by binding to FKBP12, forming a complex that inhibits mTOR signaling, thus affecting processes like protein synthesis and autophagy. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a significant role in cell growth, proliferation, and survival. Wortmannin binds to the PI3K catalytic domain, blocking its activity and thus affecting downstream signaling pathways like AKT. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A natural product that acts as a broad-spectrum inhibitor of protein kinases. It blocks ATP binding to kinase domains, thereby inhibiting a wide range of kinases involved in cell cycle regulation, apoptosis, and other cellular functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Similar to Wortmannin, it is a PI3K inhibitor but with a different binding mechanism. It competes with ATP for binding to PI3K, thus preventing the activation of downstream signaling pathways involved in cell growth and survival. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Specifically targets p38 MAP kinase, an important molecule in cellular responses to stress and inflammation. By inhibiting p38, SB203580 modulates the production of inflammatory cytokines and affects cell cycle progression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Selectively inhibits MEK (MAPK/ERK kinase), which is upstream of ERK in the MAPK signaling pathway. By blocking MEK, PD98059 disrupts the activation of ERK, which plays a crucial role in cell division and differentiation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits c-Jun N-terminal kinase (JNK), which is involved in controlling apoptosis, cellular differentiation, and immune responses. By blocking JNK, SP600125 can influence cell death processes and inflammatory responses. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Acts as a DNA methyltransferase inhibitor, leading to reduced DNA methylation. This alteration in epigenetic regulation can lead to reactivation of silenced genes, impacting cell differentiation and potentially inhibiting cancer cell growth. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase (HDAC) inhibitor, affecting gene expression by altering chromatin structure. This leads to increased histone acetylation, resulting in a more open chromatin state and thus affecting the transcription of various genes. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Specifically inhibits the Hedgehog signaling pathway, which is crucial in embryonic development and has been implicated in the progression of certain cancers. Cyclopamine acts by binding to and inhibiting Smoothened, a key component of this pathway. | ||||||